Sign In
to Vote &
Create Storyboards.
 

AesRx anti-sickling drug AES-103 begins Phase 2 trial

Medical News Today - 9 Sep 2013 11:00
AesRx, LLC, announced it has received regulatory and ethics committee approval for a Phase 2 clinical trial of its novel Aes-103 anti-sickling agent in patients with sickle cell disease (SCD). The Company plans for patient enrollment to start this month. This is the first Phase 2 trial of Aes-103 for SCD and as such marks an important milestone in the drug's development. This double-blind, placebo controlled study will evaluate the safety and pharmacokinetics of 28-day dosing of Aes-103. In addi...
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard